BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients

Browse by...

Deposit

Highlights

More informations

Title		BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
Authors		Friedlaender, Alex Vuilleumier, Aurélie Viassolo, Valeria Ayme, Aurélie De Talhouet, Solène Combes, Jean-Damien Peron, Julien Bodmer, Alexandre Giraud, Sophie Buisson, Adrien Bonadona, Valerie Bouchardy, Isabelle Tredan, Olivier Chappuis, Pierre Labidi-Galy, Sana Intidhar show all authors [1 - 15]
Published in		Breast cancer research and treatment. 2019, vol. 174, no. 3, p. 775-783
Abstract		BRCA1 and BRCA2 proteins are central to DNA repair process through homologous recombination. We hypothesize that BRCA1/BRCA2 mutation carriers may exhibit increased hematological toxicity when receiving genotoxic chemotherapy.
Identifiers		DOI: 10.1007/s10549-018-05127-2 PMID: 30635808
Full text		Article (Published version) (999 Kb) - Limited access to UNIGE
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine Faculté de médecine / Section de médecine fondamentale / Département de pathologie et immunologie
Citation (ISO format)		FRIEDLAENDER, Alex et al. BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients. In: Breast Cancer Research and Treatment, 2019, vol. 174, n° 3, p. 775-783. doi: 10.1007/s10549-018-05127-2 https://archive-ouverte.unige.ch/unige:120074